Lumos Diagnostics, a leader in rapid point-of-care (POC) diagnostic technologies, will collaborate with the Victorian Government to establish a manufacturing capability in Rapid Antigen Tests (RAT) in Victoria.
As part of the agreement, Lumos will receive a support package to establish the facility, subject to meeting a number of requirements, including successfully securing approval from the Australian Therapeutic Goods Administration (TGA) for its COVID-19 RAT test, CoviDx.
Sam Lanyon, Executive Chair of Lumos Diagnostics, said that in addition to co-investing with Lumos to progressively establish a $17.2 million Diagnostics Manufacturing Facility and Innovation Hub in Victoria, the State Government would also be an early purchaser of the CoviDx RATs.
“Lumos Diagnostics is proud to collaborate with the Victorian Government to manufacture and deliver critical, rapid diagnostic tests,” Mr Lanyon stated.
“Lumos will leverage its existing partnerships and global experience that has seen it create critical infrastructure and world-class technology in North America, to support the establishment of a Victorian manufacturing and innovation hub for rapid diagnostics.
“We are thrilled that as an organisation that was founded in Victoria, we can support the creation of local jobs whilst future proofing Victoria’s needs for rapid testing.”
According to Mr Lanyon, the facility aims to produce 1 million tests initially and up to 50 million rapid tests per year by introducing greater automation and expanding production lines subject to market demand.
